Double immunotherapy attack shows promise for tough lung cancer

NCT ID NCT04736173

Ongoing Disease control Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The study includes 169 participants and aims to see if the combination helps keep the cancer from growing longer than standard treatments. Researchers are also checking overall survival, tumor shrinkage, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Zimberelimab and domvanalimab (two immunotherapy drugs)

What this could lead to

If successful, this combination could offer a new first-line treatment option for people with advanced lung cancer that has high PD-L1 levels, potentially improving how long they live without their cancer worsening.

What could go wrong

This is a mid-stage trial with only 169 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation in healthy organs, and the combination may not work better than existing treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER NON-SMALL-CELL LUNG CANCER NONSQUAMOUS NON SMALL CELL LUNG CANCER SQUAMOUS NON-SMALL-CELL LUNG CANCER

Contacts and locations

Show contact details

Locations

Research Site

Columbus, Georgia, 31904, United States
Research Site

Kingwood, Texas, 77339, United States
Research Site

Blacksburg, Virginia, 24060, United States
Research Site

Hong Kong, Hong Kong
Research Site

Johor Bahru, Malaysia
Research Site

Kuala Lumpur, Malaysia
Research Site

Kuantan, Malaysia
Research Site

Kuching, Malaysia
Research Site

Pulau Pinang, Malaysia
Research Site

Putrajaya, Malaysia
Research Site

Davao City, Philippines
Research Site

Manila, Philippines
Research Site

George, South Africa
Research Site

Johannesburg, South Africa
Research Site

Pretoria, South Africa
Research Site

Daegu, South Korea
Research Site

Incheon, South Korea
Research Site

Jinju, South Korea
Research Site

Seoul, South Korea
Research Site

Suwon, South Korea
Research Site

Taichung, Taiwan
Research Site

Bangkok, Thailand
Research Site

Changwat Sara Buri, Thailand
Research Site

Chanthaburi, Thailand
Research Site

Chiang Mai, Thailand
Research Site

Khon Kaen, Thailand
Research Site

Lampang, Thailand
Research Site

Nakhon Nayok, Thailand
Research Site

Nakhon Ratchasima, Thailand
Research Site

Phitsanulok, Thailand
Research Site

Songkhla, Thailand
Research Site

Ubon Ratchathani, Thailand
Research Site

Adana, Turkey (Türkiye)
Research Site

Ankara, Turkey (Türkiye)
Research Site

Edirne, Turkey (Türkiye)
Research Site

Istanbul, Turkey (Türkiye)
Research Site

Kocaeli, Turkey (Türkiye)
Research Site

Hanoi, Vietnam
Research Site

Huế, Vietnam